vs
Side-by-side financial comparison of ICU MEDICAL INC (ICUI) and Solstice Advanced Materials Inc. (SOLS). Click either name above to swap in a different company.
Solstice Advanced Materials Inc. is the larger business by last-quarter revenue ($969.0M vs $540.7M, roughly 1.8× ICU MEDICAL INC). ICU MEDICAL INC runs the higher net margin — -2.9% vs -3.6%, a 0.7% gap on every dollar of revenue. On growth, Solstice Advanced Materials Inc. posted the faster year-over-year revenue change (6.8% vs -14.1%). Solstice Advanced Materials Inc. produced more free cash flow last quarter ($41.0M vs $36.0M).
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
Solstice Advanced Materials Inc. is a specialty advanced materials provider that develops, produces and distributes high-performance functional materials for renewable energy systems, consumer electronics, industrial manufacturing and advanced automotive sectors. The company focuses on material solutions that boost product durability, energy efficiency and operational performance for its global clients.
ICUI vs SOLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $540.7M | $969.0M |
| Net Profit | $-15.7M | $-35.0M |
| Gross Margin | 37.5% | 32.0% |
| Operating Margin | 1.0% | 17.9% |
| Net Margin | -2.9% | -3.6% |
| Revenue YoY | -14.1% | 6.8% |
| Net Profit YoY | 34.0% | -123.0% |
| EPS (diluted) | $-0.63 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $540.7M | — | ||
| Q3 25 | $537.0M | $969.0M | ||
| Q2 25 | $548.9M | — | ||
| Q1 25 | $604.7M | — | ||
| Q4 24 | $629.8M | — | ||
| Q3 24 | $589.1M | $907.0M | ||
| Q2 24 | $596.5M | — | ||
| Q1 24 | $566.7M | — |
| Q4 25 | $-15.7M | — | ||
| Q3 25 | $-3.4M | $-35.0M | ||
| Q2 25 | $35.3M | — | ||
| Q1 25 | $-15.5M | — | ||
| Q4 24 | $-23.8M | — | ||
| Q3 24 | $-33.0M | $152.0M | ||
| Q2 24 | $-21.4M | — | ||
| Q1 24 | $-39.5M | — |
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | 32.0% | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | 36.6% | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
| Q4 25 | 1.0% | — | ||
| Q3 25 | 2.6% | 17.9% | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 1.4% | 21.7% | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | -1.9% | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -0.6% | -3.6% | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -5.6% | 16.8% | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | -7.0% | — |
| Q4 25 | $-0.63 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $1.43 | — | ||
| Q1 25 | $-0.63 | — | ||
| Q4 24 | $-0.97 | — | ||
| Q3 24 | $-1.35 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-1.63 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $417.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.1B | $3.2B |
| Total Assets | $4.1B | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $417.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $308.6M | — | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | — | ||
| Q1 24 | $251.4M | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $3.2B | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | $3.2B | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | $5.2B | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | $4.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.6M | $289.0M |
| Free Cash FlowOCF − Capex | $36.0M | $41.0M |
| FCF MarginFCF / Revenue | 6.6% | 4.2% |
| Capex IntensityCapex / Revenue | 4.6% | 25.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $91.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.6M | — | ||
| Q3 25 | $56.7M | $289.0M | ||
| Q2 25 | $11.2M | — | ||
| Q1 25 | $51.3M | — | ||
| Q4 24 | $40.2M | — | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $82.0M | — | ||
| Q1 24 | $45.8M | — |
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | $41.0M | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — | ||
| Q1 24 | $29.9M | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | 4.2% | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | 25.6% | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
SOLS
| Refrigerants | $400.0M | 41% |
| Research And Performance Chemicals | $126.0M | 13% |
| Electronic Materials | $103.0M | 11% |
| Other | $89.0M | 9% |
| Services | $64.0M | 7% |
| Alternative Energy Services | $63.0M | 7% |
| Safety And Defense Solutions | $53.0M | 5% |
| Healthcare Packaging | $49.0M | 5% |
| Affiliated Entity | $22.0M | 2% |
